SAN DIEGO – Results for the first quarter of fiscal year 2025 at ResMed are in with revenue up by 11% to $1.2 billion. Income from operations increased 34% with non-GAAP income from operations up 27%. “Our first-quarter fiscal year 2025 results reflect ongoing momentum and strong execution across all areas of our business,” said Mick Farrell, Chairman and CEO of ResMed. “We delivered 11% year-over-year revenue growth, and our focus on operational excellence resulted in another quarter of year-over-year margin expansion and a 34% increase in operating profit.
“As we celebrate 35 years of growth and innovation, our recently launched 2030 strategy will further enable us to transform sleep health, breathing health, and healthcare technology at home,” Farrell continued via press release. “By building on our leadership in connected digital health, we are driving better care, simplifying the health journey, and improving access to our therapies globally so even more people worldwide are empowered to live healthier, higher-quality lives using products and services they love.”
Net income for the quarter was $311 million and diluted earnings per share was $2.11. Non-GAAP net income increased by 35 percent to $325 million, and non-GAAP diluted earnings per share increased by 34 percent to $2.20, predominantly attributable to strong sales growth and gross margin improvement.